Mechanism of Action
GLP-1 Receptor Agonism
Exendin-4 binds and activates the GLP-1 receptor (GLP-1R) with comparable potency to native GLP-1. GLP-1R is Gs-coupled and elevates cAMP in pancreatic beta cells, potentiating glucose-stimulated insulin secretion. Exendin-4 also suppresses glucagon, slows gastric emptying, reduces appetite (CNS GLP-1R), and promotes beta cell survival. Its DPP-4 resistance gives it a half-life of ~2.4 hours vs ~2 minutes for native GLP-1.
CNS and Appetite Effects
GLP-1R in the hypothalamus, brainstem, and reward circuits mediates the appetite-suppressing effects of exendin-4. Central GLP-1R activation reduces food intake, decreases meal size, and modulates hedonic eating. These CNS effects contribute significantly to the weight loss observed with GLP-1 agonist therapy.
Research Summary
Type 2 Diabetes
FDA ApprovedExenatide (Byetta) was the first approved GLP-1 receptor agonist (2005). It reduces HbA1c by ~0.8-1.1%, promotes weight loss of 2-3 kg, and carries low hypoglycemia risk. Bydureon (weekly microsphere formulation) achieves comparable glycemic control with improved adherence.
Neuroprotection
Clinical ResearchExendin-4 crosses the blood-brain barrier and shows neuroprotective effects in Parkinson's and Alzheimer's disease models. A clinical trial in Parkinson's disease showed slower motor decline with exenatide vs placebo over 48 weeks, generating significant interest in GLP-1R agonists for neurodegeneration.
Cardiovascular Effects
Clinical EvidenceThe EXSCEL trial of exenatide weekly in T2DM patients showed a non-significant trend for cardiovascular benefit. Other GLP-1 agonists (liraglutide, semaglutide) have shown more significant cardiovascular benefit. Exenatide did not demonstrate the same magnitude of benefit, possibly due to formulation differences.
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| T2DM treatment (exenatide BID) | 5 ug SC twice daily x 4 weeks, then 10 ug twice daily | Twice daily | Subcutaneous |
| T2DM (Bydureon weekly) | 2 mg SC weekly | Once weekly | Subcutaneous |
| Neuroprotection research (rodent) | 10 ug/kg SC | Daily x 4-8 weeks | Subcutaneous |
Exenatide is used only for T2DM and obesity under physician supervision. Not for athletic performance.
Interactions
Safety Profile
Common: nausea (40%), vomiting, diarrhea. Rare: pancreatitis (black box warning, discontinue if suspected). Injection site nodules (Bydureon). Renal impairment may increase exposure; not recommended with eGFR < 30. Thyroid C-cell tumors in rodents at high doses (class concern). Not WADA-listed.
References
- [1]Eng J, et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. J Biol Chem. 1992;267(11):7402-7405.
- [2]Buse JB, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27(11):2628-2635.
- [3]Athauda D, et al. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10103):1664-1675.